Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

Seeks nod as both primary and precaution dose

Bharat Biotech
Premium

Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including Gujarat, Karnataka, Maharashtra and Telangana

Sohini Das Mumbai


Bharat Biotech has submitted data from Phase 3 clinical trials of BBV154, its intranasal Covid vaccine candidate, to the drug regulator. It has sought approval both as a primary two-dose vaccine, and a heterologous booster shot.

A heterologous booster implies that the third or subsequent dose of the vaccine is different from its primary dose. Typically, the primary dose comprises two shots. The Hyderabad-based company claimed that BBV154, which is stable at 2-8 degrees Celsius, is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials.

“Being an intranasal vaccine, BBV154 may produce local antibodies in the upper

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 15 2022 | 6:49 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com